Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Bell Gardens, CA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Bell Gardens, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Downey, CA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Downey, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
West Covina, CA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
West Covina, CA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Thornton, CO
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Thornton, CO
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Hartford, CT
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Hartford, CT
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Gainesville, FL
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Miami, FL
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Pensacola, FL
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Columbus, GA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Columbus, GA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Nampa, ID
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Nampa, ID
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Hutchinson, KA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Hutchinson, KA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Topeka, KA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Lebanon, NH
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Durham, NC
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Durham, NC
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Mayfield Heights, OH
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Greenville, SC
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Alcoa, TN
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Alcoa, TN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site 1
mi
from
Austin, TX
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site 1
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Fort Sam Houston, TX
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Madison, WI
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Milwaukee, WI
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Hobart,
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Hobart,
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Investigational Site
mi
from
Metairie, LA
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Saint Paul, MN
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated:  12/31/1969
Regeneron Study Site
mi
from
Saint George, UT
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants
Status: Enrolling
Updated: 12/31/1969
Regeneron Study Site
mi
from
Saint George, UT
Click here to add this to my saved trials
COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Prospective, Non‐Randomized, Single Arm, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Prospective, Non‐Randomized, Single Arm, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Vero Beach, FL
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jamaica, NY
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jamaica, NY
Click here to add this to my saved trials
Integrating Supportive Care in Cystic Fibrosis
Integrating Supportive Care in Cystic Fibrosis: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Integrating Supportive Care in Cystic Fibrosis
Integrating Supportive Care in Cystic Fibrosis: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Cardiopulmonary Outpatient Rehabilitation Using Mobile Technology
Empowering Individuals Post-Cardiopulmonary Outpatient Rehabilitation to Continue to Live a Heart Healthy Lifestyle: Utilizing Mobile Health Technology
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
mi
from
New York, NY
Cardiopulmonary Outpatient Rehabilitation Using Mobile Technology
Empowering Individuals Post-Cardiopulmonary Outpatient Rehabilitation to Continue to Live a Heart Healthy Lifestyle: Utilizing Mobile Health Technology
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis
Manometry- Versus Symptom-Guided Large Volume Thoracentesis: a Randomized Controlled Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis
Manometry- Versus Symptom-Guided Large Volume Thoracentesis: a Randomized Controlled Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, CA
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Pneumonia in the Intensive Care Unit (ICU) Setting
Pneumonia in the Intensive Care Unit (ICU) Setting
Status: Enrolling
Updated:  12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Pneumonia in the Intensive Care Unit (ICU) Setting
Pneumonia in the Intensive Care Unit (ICU) Setting
Status: Enrolling
Updated: 12/31/1969
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
AL Adult Birmingham / The Children's Hospital Atlanta
mi
from
Birmingham, AL
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
AL Adult Birmingham / The Children's Hospital Atlanta
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Denver Adult / National Jewish Health
mi
from
Denver, CO
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Denver Adult / National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Atlanta Emory Adult / Emory University Hospital
mi
from
Atlanta, GA
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Atlanta Emory Adult / Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Chicago Northwestern Adult / Northwestern Memorial Hospital
mi
from
Chicago, IL
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Chicago Northwestern Adult / Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Iowa City University of Iowa Adult / University of Iowa Hospitals & Clinics
mi
from
Iowa City, IA
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Iowa City University of Iowa Adult / University of Iowa Hospitals & Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Lexington, KY Adult / University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Lexington, KY Adult / University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Portland, ME Adult
mi
from
Portland, ME
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Portland, ME Adult
mi
from
Portland, ME
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Baltimore Hopkins Adult / John Hopkins Hospital
mi
from
Baltimore, MD
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Baltimore Hopkins Adult / John Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Boston CHB Adult / Boston Children's Hospital (BCH)
mi
from
Boston, MA
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Boston CHB Adult / Boston Children's Hospital (BCH)
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Minneapolis CC and Adult / University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Minneapolis CC and Adult / University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Omaha Adult / The Nebraska Medical Center
mi
from
Omaha, NE
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Omaha Adult / The Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Lebanon, NH Dartmouth-Hitchcock CC and Adult / Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Lebanon, NH Dartmouth-Hitchcock CC and Adult / Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Columbus CC and Peds / Nationwide Children's Hospital
mi
from
Columbus, OH
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Columbus CC and Peds / Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Toledo, OH CC and Peds / The Toledo Hospital; Toledo Children's Hospital
mi
from
Toledo, OH
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Toledo, OH CC and Peds / The Toledo Hospital; Toledo Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated:  12/31/1969
Oklahoma City Adult / Presbyterian Hospital at OU Medical Center
mi
from
Oklahoma City, OK
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)
Status: Enrolling
Updated: 12/31/1969
Oklahoma City Adult / Presbyterian Hospital at OU Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials